The battle against HIV in sub-Saharan Africa has always been as much about systems and science as about the virus itself. Antiretroviral therapy has turned what was once a death sentence into a ...

When your body’s immune cells attack you instead of protecting you, today’s treatments tamp down the friendly fire but they ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

Rohit Loomba, M.D., will hold the new endowed chair that was established in honor of the late biotech leader John C. Martin to further liver disease research ...

The trial evaluated treatment responses in patients who were virologically suppressed, switching from a multi-tablet regimen ...

Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an investigational single-tablet regimen for the treatment of HIV-1.

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...

The first complainant alleged he had been repeatedly raped at Mr Hall's home in 2015 after the pair met in a bar, the court ...

Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...

NVA’s cast of 14 brings Jonathan Larson’s 1996 rock musical to life. This works well in the intimate 100-seat theater.

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...